NO20065732L - 4-Hydroksy-4-metylpiperidin-1-karboksylsyre (4-metoksy-7-morfolin-4-yl-benzotiazol-2-yl)-amid - Google Patents

4-Hydroksy-4-metylpiperidin-1-karboksylsyre (4-metoksy-7-morfolin-4-yl-benzotiazol-2-yl)-amid

Info

Publication number
NO20065732L
NO20065732L NO20065732A NO20065732A NO20065732L NO 20065732 L NO20065732 L NO 20065732L NO 20065732 A NO20065732 A NO 20065732A NO 20065732 A NO20065732 A NO 20065732A NO 20065732 L NO20065732 L NO 20065732L
Authority
NO
Norway
Prior art keywords
disease
benzothiazol
methylpiperidine
morpholin
methoxy
Prior art date
Application number
NO20065732A
Other languages
English (en)
Other versions
NO336939B1 (no
Inventor
Jean Luc Moreau
Sonia Maria Poli
Claus Riemer
Lucinda Steward
Alexander Flohr
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34967309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065732(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20065732L publication Critical patent/NO20065732L/no
Publication of NO336939B1 publication Critical patent/NO336939B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelsen med formel som er 4-hydroksy-4-metylpiperidin-1 -karboksylsyre(4-metoksy-7-morfolin-4-yl-benzotiazol-2-yl)-amid, samt farmasøytisk akseptable syreaddisjonssalter derav. Det er funnet at forbindelsen er anvendelig for behandling eller forebygging av Alzheimers sykdom, Parkinsons sykdom, Huntingtons sykdom, nevrobeskyttelse, schizofreni, angst, smerte, respirasjonsmangler, depresjon, ADHD (oppmerksomhetssvikt-hyperaktivitetslidelse), medikamentavhengighet overfor amfetaminer, kokain, opioider, etanol, nikotin, kannabinoider eller for behandling av astma, allergiske reaksjoner, hypoksi, ischemi, krampeanfall, stoffmisbruk eller for anvendelse som muskelavslappende midler, antipsykotiske midler, antiepileptiske midler, antikrampemidler og hjertebeskyttende midler.
NO20065732A 2004-05-24 2006-12-12 4-hydroksy-4-metylpiperidin-1-karboksylsyre (4-metoksy-7-morfolin-4-yl-benzotiazol-2-yl)-amid, fremstilling av denne, medikament inneholdende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom NO336939B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102262 2004-05-24
PCT/EP2005/005329 WO2005116026A1 (en) 2004-05-24 2005-05-17 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Publications (2)

Publication Number Publication Date
NO20065732L true NO20065732L (no) 2006-12-22
NO336939B1 NO336939B1 (no) 2015-11-30

Family

ID=34967309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065732A NO336939B1 (no) 2004-05-24 2006-12-12 4-hydroksy-4-metylpiperidin-1-karboksylsyre (4-metoksy-7-morfolin-4-yl-benzotiazol-2-yl)-amid, fremstilling av denne, medikament inneholdende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom

Country Status (38)

Country Link
US (1) US7368446B2 (no)
EP (1) EP1753760B1 (no)
JP (1) JP4668265B2 (no)
CN (1) CN1956983B (no)
AR (1) AR048973A1 (no)
AT (1) ATE382619T1 (no)
AU (1) AU2005247567B2 (no)
BR (1) BRPI0511543B1 (no)
CA (1) CA2567703C (no)
CR (1) CR8703A (no)
CY (1) CY1108104T1 (no)
DE (1) DE602005004142T2 (no)
DK (1) DK1753760T3 (no)
DO (1) DOP2005000091A (no)
EA (1) EA011279B1 (no)
EC (1) ECSP067018A (no)
ES (1) ES2297710T3 (no)
GT (1) GT200500124A (no)
HN (1) HN2005000238A (no)
HR (1) HRP20080027T3 (no)
IL (1) IL179364A (no)
MA (1) MA28601B1 (no)
MX (1) MXPA06013417A (no)
MY (1) MY140011A (no)
NO (1) NO336939B1 (no)
NZ (1) NZ550763A (no)
PA (1) PA8633901A1 (no)
PE (1) PE20060274A1 (no)
PL (1) PL1753760T3 (no)
PT (1) PT1753760E (no)
RS (1) RS50574B (no)
SI (1) SI1753760T1 (no)
SV (1) SV2006002125A (no)
TN (1) TNSN06371A1 (no)
TW (1) TWI358297B (no)
UA (1) UA87142C2 (no)
WO (1) WO2005116026A1 (no)
ZA (1) ZA200609136B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
EP3473251B1 (en) 2002-12-20 2023-12-13 NicoNovum AB A nicotine-cellulose combination
CA2646942C (en) 2006-03-16 2014-07-29 Modoral Brands Inc. Improved snuff composition
JP2010534674A (ja) * 2007-07-23 2010-11-11 シノシア・セラピューティクス 心的外傷後ストレス障害の治療用４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド
NZ593473A (en) 2009-01-12 2013-02-22 Pfizer Ltd Sulfonamide derivatives
US8168785B2 (en) 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
JP6042968B2 (ja) * 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
HK1252549A1 (zh) 2015-06-19 2019-05-31 Biotie Therapies, Inc. 控释tozadenant制剂
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
JP7287951B2 (ja) * 2017-08-21 2023-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしてのキノキサリン誘導体
CA3073333A1 (en) 2017-08-21 2019-02-28 Merck Patent Gmbh Bezimidazole derivatives as adenosine receptor antagonists
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
EP3897653A1 (en) 2018-12-20 2021-10-27 Biotie Therapies, Inc. Methods for treating cancer using tozadenant
DE102019110904B4 (de) 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
CN116407539B (zh) * 2021-12-30 2025-01-10 上海现代药物制剂工程研究中心有限公司 依匹哌唑甲基脂肪酸酯的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
NL7109150A (no) 1970-07-06 1972-01-10
US4028374A (en) 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de) 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
KR930005004B1 (ko) 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
WO1990015801A1 (en) 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
ATE103589T1 (de) 1989-11-10 1994-04-15 Agrolinz Agrarchemikalien Verfahren zur herstellung reiner, unsymmetrisch disubstituierter harnstoffe.
JP2759228B2 (ja) 1992-05-21 1998-05-28 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
FR2753970B1 (fr) 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja) 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
BR9814956A (pt) 1997-11-10 2000-10-03 Bristol Myers Squibb Co Inibidores de benzotiazol da tirosina cinase de proteìna
WO1999037630A1 (en) 1998-01-23 1999-07-29 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
AU6280199A (en) 1998-09-30 2000-04-17 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU2000250030A1 (en) 2000-05-12 2001-11-26 Corning Incorporated Method for manufacturing an optical fiber preform with a protective coating
DE60132777T2 (de) * 2000-06-21 2009-02-12 F. Hoffmann-La Roche Ag Benzothiazolderivate zur behandlung von alzheimer und parkinson
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives

Also Published As

Publication number Publication date
ZA200609136B (en) 2008-07-30
GT200500124A (es) 2005-12-26
DK1753760T3 (da) 2008-04-14
IL179364A0 (en) 2007-03-08
EA011279B1 (ru) 2009-02-27
PE20060274A1 (es) 2006-04-14
ES2297710T3 (es) 2008-05-01
WO2005116026A1 (en) 2005-12-08
NO336939B1 (no) 2015-11-30
EP1753760B1 (en) 2008-01-02
SV2006002125A (es) 2006-02-15
CN1956983A (zh) 2007-05-02
CN1956983B (zh) 2010-05-26
ATE382619T1 (de) 2008-01-15
SI1753760T1 (sl) 2008-04-30
US7368446B2 (en) 2008-05-06
CA2567703C (en) 2013-03-05
HK1105199A1 (en) 2008-02-06
PL1753760T3 (pl) 2008-06-30
AU2005247567B2 (en) 2010-09-02
PA8633901A1 (es) 2006-05-16
IL179364A (en) 2013-01-31
HRP20080027T3 (hr) 2008-05-31
RS50574B (sr) 2010-05-07
CR8703A (es) 2007-10-04
EA200602048A1 (ru) 2007-06-29
CA2567703A1 (en) 2005-12-08
CY1108104T1 (el) 2014-02-12
TWI358297B (en) 2012-02-21
TW200612937A (en) 2006-05-01
MY140011A (en) 2009-11-30
UA87142C2 (en) 2009-06-25
MXPA06013417A (es) 2007-01-23
EP1753760A1 (en) 2007-02-21
JP2008500295A (ja) 2008-01-10
DOP2005000091A (es) 2005-06-29
NZ550763A (en) 2010-07-30
DE602005004142T2 (de) 2009-01-02
BRPI0511543A (pt) 2008-01-02
TNSN06371A1 (fr) 2008-02-22
DE602005004142D1 (de) 2008-02-14
US20050261289A1 (en) 2005-11-24
AU2005247567A1 (en) 2005-12-08
BRPI0511543B1 (pt) 2022-05-10
ECSP067018A (es) 2006-12-29
AR048973A1 (es) 2006-06-14
MA28601B1 (fr) 2007-05-02
HN2005000238A (es) 2008-07-14
JP4668265B2 (ja) 2011-04-13
PT1753760E (pt) 2008-02-12

Similar Documents

Publication Publication Date Title
NO20065732L (no) 4-Hydroksy-4-metylpiperidin-1-karboksylsyre (4-metoksy-7-morfolin-4-yl-benzotiazol-2-yl)-amid
YU96502A (sh) Derivati benzotiazola
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
BRPI0409109A (pt) novos compostos
WO2008005534A3 (en) Orally dissolving formulations of memantine
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
CN104059013B8 (zh) 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
WO2008153937A3 (en) Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2005090296A3 (en) N-substituted benzene sulfonamides
DE502005010170D1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
DE602004025935D1 (de) Histondeacetylaseinhibitor und verfahren zu dessen herstellung
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
DE502005008878D1 (de) Para-alkyl-substituierte n-(4-hydroxy-3-methoxy-benzyl)-zimtsäeureamide und deren verwendung zur herstellung von arzneimitteln
IL184439A0 (en) 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1
ATE499099T1 (de) Substituierte tetrahydro- chinolinsulfonamidverbindungen, ihre herstellung und ihre verwendung als medikamente
IL188109A0 (en) Chloro-substituted guanidines
BRPI0513510A (pt) benzotiazóis substituìdos
JO2502B1 (en) 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid-4) methoxy-7-morpholine-4-yl-benzothiazole-2-yl) -amide

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees